Xenon Seven

Xenon Seven

Director, Payer Accounts - West Region

United States · Director

Sponsorship not specifiedDetected 6 days ago
RESTNegotiationClinical TrialsPatient CareLeadershipCommunicationCollaboration

About the role

  • The National Account Director, Payer Accounts will play a critical leadership role in shaping and executing our U.S. market access strategy with national and large regional commercial payers in preparation for our first launch of Azetukalner in epilepsy.
  • We are seeking individuals that are strategic thinkers who thrive in a fast-paced, startup environment, and can contribute across the organization for success.
  • This position reports to the Senior Director, Payer Accounts, and will be fully remote.

Responsibilities

  • Establish and maintain multiple touch points at strategic payer accounts, including senior executives, to communicate the Xenon payer value story
  • Navigate payer organizations to build long-term relationships with key decision makers and potential influencers paving the way for the pipeline of innovative products from Xenon
  • Develop strategic business plans by account
  • Evaluate contracting opportunities that are consistent with Xenon's goals. Lead the contract process from initiation to negotiation/completion. Manage ongoing contracts with quarterly business reviews and evaluate ROI
  • Develop and propose short- and long-term objectives for the function in accordance with overall Company strategies and plans
  • Plan and manage budget proposals and approved budgets in accordance with the Company's strategic and operating plans and Finance policies
  • Recruit, lead, direct, develop, coach and evaluate direct reports, if any, in accordance with the Company's Human Resource policies and practices
  • ability to apply analytical insight to drive account performance and ability to "ask the right questions" of analytical resources

Requirements

  • Minimum of 10-12 years of market access experience, in biotech pharmaceuticals with at least 5 years calling on national accounts
  • Minimum of a bachelor's degree required; advanced degree a plus

Nice to have

  • Minimum of a bachelor's degree required
  • advanced degree a plus

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Benefits

  • Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown.
  • Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.
  • Securing Coverage & Access
  • Secure access and coverage rapidly for all Xenon products that is at parity with key competitors in respective classes
  • Assist in field training on access and reimbursement
  • Deliver payer insights back to market access, medical affairs, and patient services as appropriate.

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • This is a critical, field-based role responsible for building relationships with targeted customers, communicating our value proposition and securing favorable access to minimize hurdles for the patients we serve.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.